RT Journal Article
SR Electronic
T1 The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2541
OP 2547
VO 37
IS 5
A1 TAKEAKI MIYATA
A1 TSUNEHIRO OYAMA
A1 TAKASHI YOSHIMATSU
A1 HANAE HIGA
A1 DAIGO KAWANO
A1 ATSUSHI SEKIMURA
A1 NAOKI YAMASHITA
A1 TETSUYA SO
A1 AKINOBU GOTOH
YR 2017
UL http://ar.iiarjournals.org/content/37/5/2541.abstract
AB Background/Aim: Aldehyde dehydrogenase-1A1 (ALDH1A1) and CD133 have been identified as markers of cancer stem cells (CSCs). We investigated the expression of these markers and their clinical significance in lung adenocarcinoma. Materials and Methods: An immunohistochemical analysis of ALDH1A1 and CD133 expression of 92 lung adenocarcinomas was performed. The association between the expression of both markers and cancer-related death and recurrence was determined. Results: Cancer-related death and tumor recurrence were observed in 15 and 17 cases, respectively. The expression of CD133, but not ALDHA1A, was significantly associated with poorer overall survival (p<0.0001) and shorter disease-free interval (DFI) (p<0.0001). Multivariate analysis revealed that double negativity was independently associated with increased survival (hazard ratio(HR)=16.1, p=0.0004) and a longer DFI (HR=9.5, p=0.0007). Conclusion: We propose that as a functional marker, ALDH1A1 positivity may influence the viability of CSCs. The findings suggest that it is important to evaluate the expression of both markers.